NeuralCipher Research overview
The text below is the source article’s original abstract under a verified reuse license. cc by
BackgroundReduced cardiac uptake on 123Iodine-metaiodobenzylguanidine (MIBG) scintigraphy is a valuable tool for differentiating neurodegenerative parkinsonism but interpretation can be difficult due to comorbidities and drug-tracer interactions.ObjectivesThis study investigated factors limiting the clinical applicability of MIBG scintigraphy in everyday clinical practice.MethodsPatient records (2021-2022) were retrospectively reviewed, independent of whether MIBG scintigraphy was performed, for comorbidities and concomitant medication confounding its interpretation.ResultsSix hundred ninety five patients (640 Parkinson's disease, 22 multiple system atrophy, 33 progressive supranuclear palsy) were included. Factors potentially influencing cardiac MIBG binding were present in 55.3% with 18.1% exhibiting multiple factors. Medications with known drug-tracer interactions were found in 46.9% and comorbidities associated with reduced cardiac MIBG uptake in 20.9%.ConclusionsThe clinical utility of MIBG scintigraphy is frequently restricted by medications and comorbidities highlighting the need of careful planning in clinical practice.
Scientific assessment
Research question
Assess the question within the original study’s scope.
Methods & sample
Check the source article for study design and sample details.
Key findings
An editorially approved findings summary is not yet published for this record.
Limitations
Generalizability, bias and clinical meaning require separate assessment.
Methods, samples and clinical conclusions are not inferred from bibliographic metadata.